Emerging Therapies in Oncology: From Phase I And Beyond
This workshop will provide a unique opportunity for oncologists and other health professionals to hear from leading experts in medical oncology as well as clinical and translational research. This educational workshop is directed toward medical oncologists, translational researchers (MDs and PhDs), and drug developers from academia and industry interested in cancer drug development. Other health professionals interested in the treatment of cancer are also invited to attend.
After attending this conference, participants should be able to:
• Incorporate the appropriate referral of patients for consideration of clinical trials into clinical practice (knowledge, competence, performance);
• Incorporate the latest data on novel therapies for common cancers into clinical practice (knowledge, competence, performance);
• Assimilate the latest emerging therapies or refer patients for consideration of clinical trials to improve patient outcomes (knowledge, competence, performance, patient outcomes); and
• Practice precision medicine and incorporate appropriate tests in clinical practice (knowledge, competence, performance, patient outcomes).
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Click here to view the program brochure.
For more program information and registration, visit: https://www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/emerging-therapies-in-oncology—from-phase-i-and-beyond.html
The University of Texas MD Anderson Cancer Center
Dan L. Duncan Building (CPB), Floor 8
1155 Pressler St.
Houston Texas 77030